Quick Answer
Gossamer Bio, Inc. reported Diluted EPS of $0.75 per share (loss) for fiscal year 2025.
Gossamer Bio, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.75 | -200.0% |
| 2024 | -$0.25 | +78.8% |
| 2023 | -$1.18 | +56.5% |
| 2022 | -$2.71 | +13.4% |
| 2021 | -$3.13 | +11.8% |
| 2020 | -$3.55 | -7.9% |
| 2019 | -$3.29 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.21 | -50.0% | -23.5% |
| June 30, 2025 | -$0.17 | -177.3% | -6.3% |
| March 31, 2025 | -$0.16 | +15.8% | -14.3% |
| September 30, 2024 | -$0.14 | +33.3% | -163.6% |
| June 30, 2024 | $0.22 | +148.9% | +215.8% |
| March 31, 2024 | -$0.19 | +63.5% | +9.5% |
| September 30, 2023 | -$0.21 | +67.7% | +53.3% |
| June 30, 2023 | -$0.45 | +39.2% | +13.5% |
- Gossamer Bio, Inc. showed a decrease of -200.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2025 period, Gossamer Bio, Inc.’s diluted eps has grown by 77.2% (from $3.29 per share (loss) to $0.75 per share (loss)).
- The most recent figure is from Gossamer Bio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: